Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Tumour fraction in circulating free DNA as a biomarker of disease dynamics in metastatic prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 568

Dr Atish Choudhury - Dana-Farber Cancer Institute, Boston, USA

Dr Choudhury speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about furthering our understanding of the genomics and genetics in metastatic disease from blood samples. 

Sequencing cfDNA (circulating free DNA) deduces where the DNA originates from (tumour or not).

This quantification can be used for a lot of different applications, and correlated with clinical features.

Examples of these features are PSA, anaemia and alkaline phosphatase. 

These are all increased with and increased level of tumour derived cfDNA.

The exciting part of Dr Choudhury's research is that it may be possible to correlate response to treatment with levels of tumour derived cfDNA in the blood.

This may provide a very cheap, and early biomarker to deduce whether treatment is working. 

In the future, a more homogenous study would be beneficial, and with larger cohorts.

Although there are still areas of this research which need deeper examination, it could be a very useful biomarker in the early stages of treatment. 

Related videos

follow us

War on Cancer 2018

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation